The table below lists the top 20 global drug companies based on sales in 2009:
| S.No. | Company | Ticker | 2009 Revenues in US $ (Milllions) |
|---|---|---|---|
| 1 | Pfizer | PFE | $45,448 |
| 2 | Sanofi-Aventis | SNY | $40,871 |
| 3 | Novartis | NVS | $38,455 |
| 4 | GlaxoSmithKline | GSK | $36,746 |
| 5 | AstraZeneca | AZN | $31,905 |
| 6 | Merck & Co. | MRK | $26,929 |
| 7 | Johnson & Johnson | JNJ | $22,520 |
| 8 | Eli Lilly & Co. | LLY | $20,629 |
| 9 | Bristol-Myers Squibb | BMY | $18,808 |
| 10 | Abbott Laboratories | ABT | $16,486 |
| 11 | Takeda Chem Ind. | TKPHY.PK | $14,204 |
| 12 | Boehringer-Ingelheim | $14,027 | |
| 13 | Teva Pharma | TEVA | $13,814 |
| 14 | Bayer Schering | BAYRY.PK | $13,344 |
| 15 | Astellas | ALPMY.PK | $10,509 |
| 16 | Daiichi-Sankyo | DSKYY.PK | $9,757 |
| 17 | Eisai | ESALY.PK | $8,441 |
| 18 | Otsuka | $7,717 | |
| 19 | Gilead Sciences | GILD | $6,469 |
| 20 | Mylan | MYL | $5,015 |
Source: Contract Pharma
Otsuka, Gilead and Mylan are new to this list. Half of the companies ranked 11-20 are based in Japan. Though currently ranked at number 13, Israel-based Teva (TEVA), the world’s largest generic drug maker, has revenue goals that could propel it into the top 7 ranks in the next few years. U.S.-based Gilead (GILD) primarily focuses on developing drugs for life-threatening diseases diseases such as HIV/AIDS, liver disease and serious cardiovascular/metabolic and respiratory conditions.
Disclosure: No positions
